Gain Therapeutics, Inc. (GANX) fundamentals score
Gain Therapeutics is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (“CNS”) disorders, lysosomal storage disorders (“LSDs”), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 3.6 out of 10, Weak long-term fundamentals
- Growth: 3.7/10
- Profitability: 1.0/10
- Financial health: 5.0/10
- Earnings quality: 7.0/10
- Valuation: 2.6/10
Scores are calculated from Gain Therapeutics, Inc.’s SEC filings, using the 12 months through 2023-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10